Innate Financial Statements From 2010 to 2024
| IPHYF Stock | USD 1.28 0.00 0.00% |
Check Innate Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Innate financial statements analysis is a perfect complement when working with Innate Pharma Valuation or Volatility modules.
Innate |
Innate Pharma Company Profit Margin Analysis
Innate Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Innate Pharma Profit Margin | (0.40) % |
Most of Innate Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Innate Pharma has a Profit Margin of -0.3999%. This is 96.43% lower than that of the Healthcare sector and 98.26% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 68.51% lower than that of the firm.
Innate Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innate Pharma competition to find correlations between indicators driving Innate Pharma's intrinsic value. More Info.Innate Pharma is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innate Pharma's earnings, one of the primary drivers of an investment's value.About Innate Pharma Financial Statements
Innate Pharma stakeholders use historical fundamental indicators, such as Innate Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Innate Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innate Pharma's assets and liabilities are reflected in the revenues and expenses on Innate Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innate Pharma. Please read more on our technical analysis and fundamental analysis pages.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. Innate Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 213 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Innate Pink Sheet
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out the analysis of Innate Pharma Correlation against competitors. For more detail on how to invest in Innate Pink Sheet please use our How to Invest in Innate Pharma guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.